Lesley Fitton

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

Johan Maertens, George R. Thompson, Andrej Spec et al. · The Lancet Infectious Diseases · 2025 · 35 citations · Full text

Therapeutic Options, Antifungal Agent, Invasive Fungal Diseases +4

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

Siegfried Kasper, Martin Brecher, Lesley Fitton et al. · International Clinical Psychopharmacology · 2004 · 31 citations

Phase Iiia Trials, Psychoactive Drug, Psychiatry +15

Detection of genes with moderate effects on disease resistance using ovine mhc and resistance to nematodes as an example

M.J. Stear, Alex Belch, Lesley Fitton et al. · Veterinary Immunology and Immunopathology · 2007 · 22 citations

Disease Resistance, Animal Science, Pathogenesis +10

Regulatory Activity of Endogenous and Exogenous Transforming Growth Factor β in Experimental Intestinal Immunopathology

Allan McI. Mowat, Paul Garside, Lesley Fitton et al. · Growth Factors · 1996 · 12 citations

754. Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32)

Johan Maertens, George R. Thompson, Andrej Spec et al. · Open Forum Infectious Diseases · 2022 · 10 citations · Full text